MRX Fundamental Analysis - MISTER SPEX SE

Fundamental Rating

Taking everything into account, MRX scores 2 out of 10 in our fundamental rating. MRX was compared to 57 industry peers in the Specialty Retail industry. MRX has a bad profitability rating. Also its financial health evaluation is rather negative. MRX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MRX has reported negative net income.

MRX had a negative operating cash flow in the past year.

MRX had negative earnings in each of the past 5 years.

MRX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of MRX (-45.56%) is worse than 94.74% of its industry peers.

Looking at the Return On Equity, with a value of -119.72%, MRX is doing worse than 85.96% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-45.56%
ROE	-119.72%
ROIC	N/A

ROA(3y)-27.31%

ROA(5y)-20%

ROE(3y)-57.09%

ROE(5y)-43%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 54.41%, MRX belongs to the top of the industry, outperforming 82.46% of the companies in the same industry.

In the last couple of years the Gross Margin of MRX has remained more or less at the same level.

MRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	54.41%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.74%

GM growth 5Y0.94%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MRX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for MRX has been increased compared to 1 year ago.

MRX has more shares outstanding than it did 5 years ago.

The debt/assets ratio for MRX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -2.44, we must say that MRX is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -2.44, MRX is doing worse than 80.70% of the companies in the same industry.

MRX has a Debt/Equity ratio of 0.81. This is a neutral value indicating MRX is somewhat dependend on debt financing.

MRX has a Debt to Equity ratio of 0.81. This is in the lower half of the industry: MRX underperforms 61.40% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.81
Debt/FCF	N/A
Altman-Z	-2.44

ROIC/WACCN/A

WACC6.01%

2.3 Liquidity

A Current Ratio of 2.31 indicates that MRX has no problem at all paying its short term obligations.

MRX's Current ratio of 2.31 is amongst the best of the industry. MRX outperforms 85.96% of its industry peers.

A Quick Ratio of 1.66 indicates that MRX should not have too much problems paying its short term obligations.

With an excellent Quick ratio value of 1.66, MRX belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.31
Quick Ratio	1.66

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -26.68%.

Looking at the last year, MRX shows a very negative growth in Revenue. The Revenue has decreased by -16.95% in the last year.

MRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.25% yearly.

EPS 1Y (TTM)-26.68%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%68.09%

Revenue 1Y (TTM)-16.95%

Revenue growth 3Y3.73%

Revenue growth 5Y9.25%

Sales Q2Q%-17.78%

3.2 Future

MRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.29% yearly.

The Revenue is expected to grow by 11.67% on average over the next years. This is quite good.

EPS Next Y54.33%

EPS Next 2Y31.15%

EPS Next 3Y22.29%

EPS Next 5YN/A

Revenue Next Year-15.23%

Revenue Next 2Y-6.06%

Revenue Next 3Y-2.53%

Revenue Next 5Y11.67%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MRX's earnings are expected to grow with 22.29% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y31.15%

EPS Next 3Y22.29%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MRX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

MISTER SPEX SE

FRA:MRX (1/7/2026, 5:29:03 PM)

1.28

-0.05 (-4.12%)

Chartmill FA Rating

GICS SectorConsumer Discretionary

GICS IndustryGroupConsumer Discretionary Distribution & Retail

GICS IndustrySpecialty Retail

Earnings (Last)11-13 2025-11-13/amc

Earnings (Next)N/A N/A

Inst Owners21.74%

Inst Owner ChangeN/A

Ins Owners15.2%

Ins Owner ChangeN/A

Market Cap44.86M

Revenue(TTM)185.36M

Net Income(TTM)-68.92M

Analysts77.5

Price Target4.42 (245.31%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-1%

Min Revenue beat(2)-1.02%

Max Revenue beat(2)-0.98%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)14.75%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-1.73%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-0.21%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.24
P/FCF	N/A
P/OCF	N/A
P/B	0.78
P/tB	0.83
EV/EBITDA	N/A

EPS(TTM)-2.09

EYN/A

EPS(NY)-0.42

Fwd EYN/A

FCF(TTM)-0.26

FCFYN/A

OCF(TTM)-0.15

OCFYN/A

SpS5.29

BVpS1.64

TBVpS1.55

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-45.56%
ROE	-119.72%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	54.41%
FCFM	N/A

ROA(3y)-27.31%

ROA(5y)-20%

ROE(3y)-57.09%

ROE(5y)-43%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.74%

GM growth 5Y0.94%

F-Score4

Asset Turnover1.23

Health

		Industry Rank	Sector Rank
Debt/Equity	0.81
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	7.61%
Cap/Sales	2.05%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.31
Quick Ratio	1.66
Altman-Z	-2.44

F-Score4

WACC6.01%

ROIC/WACCN/A

Cap/Depr(3y)41.44%

Cap/Depr(5y)71.03%

Cap/Sales(3y)6.28%

Cap/Sales(5y)7.09%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-26.68%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%68.09%

EPS Next Y54.33%

EPS Next 2Y31.15%

EPS Next 3Y22.29%

EPS Next 5YN/A

Revenue 1Y (TTM)-16.95%

Revenue growth 3Y3.73%

Revenue growth 5Y9.25%

Sales Q2Q%-17.78%

Revenue Next Year-15.23%

Revenue Next 2Y-6.06%

Revenue Next 3Y-2.53%

Revenue Next 5Y11.67%

EBIT growth 1Y-29.66%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year98.35%

EBIT Next 3Y32.46%

EBIT Next 5Y29.96%

FCF growth 1Y50.44%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-711.8%

OCF growth 3YN/A

OCF growth 5YN/A

MISTER SPEX SE / MRX.DE FAQ

What is the fundamental rating for MRX stock?

ChartMill assigns a fundamental rating of 2 / 10 to MRX.DE.

What is the valuation status for MRX stock?

ChartMill assigns a valuation rating of 1 / 10 to MISTER SPEX SE (MRX.DE). This can be considered as Overvalued.

Can you provide the profitability details for MISTER SPEX SE?

MISTER SPEX SE (MRX.DE) has a profitability rating of 1 / 10.

What is the earnings growth outlook for MISTER SPEX SE?

The Earnings per Share (EPS) of MISTER SPEX SE (MRX.DE) is expected to grow by 54.33% in the next year.

MISTER SPEX SE (MRX.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MISTER SPEX SE / MRX.DE FAQ

What is the fundamental rating for MRX stock?

What is the valuation status for MRX stock?

Can you provide the profitability details for MISTER SPEX SE?

What is the earnings growth outlook for MISTER SPEX SE?